Ergoteles’s Oyster Point Pharma, Inc. Common Stock OYST Stock Holding History

Ergoteles’s Portfolio OYST Stock Details OYST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-14,172	Closed	-$80K	–	2094
2022 Q3	$80K	Sell	14,172 -20,580	-59%	-$129K	﹤0.01%	1406
2022 Q2	$150K	Buy	+34,752	New	+$198K	﹤0.01%	1421

Other funds holding OYST

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Invus Financial Advisors New York $89.2M AUM 10.79% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

Westchester Capital Management (New York) Valhalla, New York $2.21B AUM 26.02% 1-Year Est. Return

Gabelli Funds Rye, New York $14.8B AUM 32.24% 1-Year Est. Return

GW&K Investment Management Boston, Massachusetts $11.3B AUM 31.98% 1-Year Est. Return

MMCAP International Grand Cayman, Cayman Islands $1.16B AUM 77.9% 1-Year Est. Return

Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Ergoteles's OYST Position: Q4 2022 in Review

Ergoteles sold out of Oyster Point Pharma, Inc. Common Stock (OYST) in Q4 2022, closing a stake of 14,172 shares — an estimated $80K sold.

Ergoteles first reported a position in OYST in Q2 2022 and held it in 2 quarters. The position peaked at $150K in Q2 2022. 53 funds tracked by Wall St. Rank hold OYST as of Q4 2022.

Ergoteles reported no remaining Oyster Point Pharma, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
Ergoteles sold 14,172 Oyster Point Pharma, Inc. Common Stock shares in Q4 2022, an estimated $80K.
Ergoteles first reported a position in Oyster Point Pharma, Inc. Common Stock in Q2 2022 and held it in 2 quarters.
Ergoteles's Oyster Point Pharma, Inc. Common Stock position peaked at $150K in Q2 2022.
53 funds tracked by Wall St. Rank held Oyster Point Pharma, Inc. Common Stock as of Q4 2022.

Based on Ergoteles's 13F filing for Q4 2022, filed 14 Feb 2023.